Stock News
PFizer’s New Colorectal Cancer Treatment: Braftovi Combo Therapy Gets Conditional Approval and Boosts Response Rates
Exciting New Developments in Metastatic Colorectal Cancer Treatment: Pfizer’s Braftovi, Cetuximab, and mFOLFOX6 Combo On a recent Saturday, Pfizer Inc., a renowned pharmaceutical corporation, unveiled the outcomes of the Phase 3 BREAKWATER trial. This trial assessed the efficacy of Braftovi (encorafenib), in partnership with cetuximab (Erbitux) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin), in patients diagnosed…
Newtek One, Inc. Announces Full-Year 2024 Earnings of $1.97 per Basic and $1.96 per Diluted Common Share
Company Announces Increased Earnings Forecast for Full Year 2025 In a recent press release, our company announced an update to its earnings forecast for the full year 2025. The new range is set between $2.10 and $2.50 per basic and diluted common share. Background Our company has been experiencing steady growth over the past few…
SEACOR Marine Reveals Q4 2024 Financial Results: An In-Depth Look
SEACOR Marine Reports Fourth Quarter 2024 Financial Results HOUSTON, Feb. 26, 2025 – SEACOR Marine Holdings Inc. (NYSE: SMHI), a prominent player in the marine and support transportation industry for offshore energy facilities worldwide, has recently released its financial results for the fourth quarter that ended on December 31, 2024. Financial Highlights The Company reported…
ArrowMark Financial Corp: Revealing the Heart of Their January 2025 Month-End Net Asset Value
ArrowMark Financial Announces Estimated Unaudited Net Asset Value for January 2025 On February 26, 2025, ArrowMark Financial Corp. (BANX) disclosed its estimated and unaudited Net Asset Value (NAV) for the month of January, which came in at $22.11. Impact on ArrowMark Financial Shareholders The NAV per share figure represents the value of each outstanding share…
Rosen Investor Counsel Urges Newmont Corporation: Insights from a Trusted Business Advisor
Important Information for Newmont Corporation Securities Purchasers: Rosen Law Firm Reminds Investors of the Lead Plaintiff Deadline Newmont Corporation (NYSE: NEM) investors who purchased the company’s securities between February 22, 2024, and October 23, 2024, inclusive (the “Class Period”), are encouraged to contact Rosen Law Firm before the April 1, 2025, lead plaintiff deadline. The…
Mesoblast Announces Pricing for Ryoncil Based on Treatment Value: Product Launch Anticipated This Quarter
Financial Results and Operational Update for Half-Year Ended December 31, 2024: A Detailed Analysis The technology sector continues to evolve at an unprecedented pace, and one of the leading players, TechGiant Inc., recently released its financial results and operational update for the half-year ended December 31, 2024. The report sheds light on the company’s financial…
Tevogen Bio CEO Celebrates Lynne Patton’s New Role as Deputy Assistant to the President and Director of Minority Outreach
Dr. Ryan Saadi Congratulates Lynne Patton on Her New Role in the White House Warren, N.J., January 27, 2025 – Dr. Ryan Saadi, the esteemed Chairman and founding CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a leading clinical-stage specialty immunotherapy biotech, recently took to the media to extend his heartfelt…
Marqeta, Inc. (MQ): Your Investment in February 2025? Kessler Topaz Meltzer Check, LLC Wants a Word!
Breaking News: Marqeta, Inc. Faces Securities Class Action Lawsuits In a recent turn of events, Marqeta, Inc., a leading modern card issuing and processing platform, has found itself in hot water. The law firm of Kessler Topaz Meltzer & Check, LLP has announced the filing of securities class action lawsuits against the company in the…